Novartis pauses enrollment in some Kisqali trials to fix manufacturing

Novartis will pause enrollment in certain clinical trials of its breast cancer drug Kisqali in order to meet regulators’ concerns around impurities related to nitrosamines, the company said Tuesday. The enrollemtn suspension will allow Novartis to adjust its manufacturing in response.